Stephen J. Blakemore

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

Antoîne Italiano, Jean‐Charles Soria, Maud Toulmonde et al. · The Lancet Oncology · 2018 · 614 citations

Medicine, Oncology, Pharmacology +12

The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia

Eytan M. Stein, Guillermo Garcia‐Manero, David A. Rizzieri et al. · Blood · 2018 · 457 citations · Full text

Life Sciences, Molecular Biology, Oncology +10

Pevonedistat (<scp>MLN</scp>4924), a First‐in‐Class <scp>NEDD</scp>8‐activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study

Ronan Swords, Harry P. Erba, Daniel J. DeAngelo et al. · British Journal of Haematology · 2015 · 234 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy

George Mulligan, David I. Lichter, Alessandra Di Bacco et al. · Blood · 2013 · 117 citations · Full text

Medicine, Hematology, Oncology +14

Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian Cancer

Steffan T. Nawrocki, Kevin R. Kelly, Peter G. Smith et al. · Clinical Cancer Research · 2013 · 117 citations

Medicine, Oncology, Pharmacology +15